Close Menu

AACR

In a training subset of the larger cohort, the company was able to develop classifiers that detected many cancers while minimizing false positives.

In a poster at this week's AACR annual meeting, researchers used the firm's tech to investigate how the addition of a cytokine agonist can improve CAR-T treatment.

Presentations largely reflected negatively on the utility of PD-L1 for stratifying response, but pivotal new data on tumor mutational burden as assessed by Foundation Medicine's genomic sequencing panel.

Investigators from several centers outlined tumor features, treatment strategies, and clinical trial classifications coming from tumor-germline clinical sequencing programs.

Conducting studies on Latina and African-American women produces population-specific insights on the genetics of the disease that aren't possible to glean in European-heavy GWAS.

Plenary session Chairwoman Elaine Mardis said the presentations made it clear how great the need is for interdisciplinary science as data becomes ever more complex.

The company presented new data from its validation of the PCR-based approach at a conference, citing plans to advance the kit for monitoring and early detection applications.

Participants shared data from head-to-head assay comparisons, reflected on the advancement of NGS and digital PCR methods, and discussed new standardization projects.

Stakeholders increasingly highlight the need for better, more standardized tools to validate and compare liquid biopsy tests, and commercial firms have responded.

Researchers at the AACR meeting this month addressed the lack of diversity in genomic datasets, noting that it could be hurting efforts to reduce cancer deaths.

Pages